Live healthier, stronger and sharper for longer
Short, frequent pieces on what changed in the science of ageing well — and our research library holds the deep dives.
SupplementsCreatine Monohydrate for Cognition: Latest 2026 Evidence
Dive into the cutting-edge research on Creatine Monohydrate's cognitive benefits, with a focus on new findings from 2025-2026 clinical trials.
PeptidesSS-31 (Elamipretide) in 2026: Latest Clinical
A deep dive into SS-31 (Elamipretide)'s most recent clinical findings, focusing on 2025-2026 data and its implications for longevity and healthspan.
ProtocolsHealthspan Foundation Protocol: 2026 Evidence
Dive into the Healthspan Foundation Protocol's 2026 evidence. We review the newest clinical trials, key updates, and revised recommendations to maximise your healthspan.
PeptidesCJC-1295: 2026’s Latest Evidence on Growth
Dive into the newest 2026 evidence surrounding CJC-1295 with DAC, examining its role in growth hormone modulation, clinical efficacy, and safety profile.
PeptidesCJC-1295: Latest 2026 Evidence and Revised
Dive into the cutting-edge research on CJC-1295, focusing on breakthroughs and revised recommendations emerging in 2026 for healthspan optimisation.
SupplementsLion's Mane: 2026 Evidence & Revised
New clinical data from 2025-2026 has refined our understanding of Lion's Mane. We explore the implications for cognitive enhancement and health.
SupplementsNMN Efficacy: Latest Evidence &
A deep dive into the newest clinical trials and meta-analyses concerning NMN, offering updated recommendations for its use in 2026.
ProtocolsStress Resilience: Latest Evidence &
Combat allostatic load with the updated Stress Resilience Protocol for 2026. This deep dive covers fresh clinical evidence, refined strategies, and new recommendations.
SupplementsL-Theanine: Unpacking the Latest 2026 Evidence
New evidence in 2025-2026 reshapes our understanding of L-Theanine's role in longevity, cognitive health, and stress management.
PeptidesRetatrutide: Latest 2026 Evidence and Revised
Retatrutide, the triple GIP/GLP-1/glucagon agonist, continues to reshape our understanding of metabolic intervention.
Wondering where to start?
Two minutes, no blood test, no sign-up — find out how you are actually ageing, and what to do about it.
The Sunday briefing
One email a week: what changed in the evidence, what it means for the markers you track, and the occasional thing worth stopping. No spam, unsubscribe anytime.